Validating Europe's De-Risked Approach
Novartis' deal on COPD compound AD 237, co-developed by Vectura and Arakis, proves that low-risk "re-profilers" can win big bucks. But the program must be right, and so must the partner's portfolio. It isn't about the technology-it's about the product.
You may also be interested in...
Two major changes have transformed the prospects for drug-delivery companies: the rise of spec pharma and Big Pharma's embrace of large-molecule therapeutics. A new group of start-ups represents strategies to take advantage of both opportunities.
The prices of drug-delivery deals have been going up -- thanks to spec pharma which has now turned almost entirely to the products of drug delivery and reformulation to re-stock their pipelines. Meanwhile, Big Pharma remains a minor player in small-molecule reformulation, but is increasingly active when it comes to macromolecules.
All drug company executives agree that innovation is the answer to the industry's woes-R&D productivity, pricing, perception, the lot. But they differ on what innovation means.